Last Updated:
4:10 pm
Friday, June 20, 2025
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
asx-imm
Market Cap
AU$372.40M
Volume
1559723
Open
0.23
AU$
High
0.24
AU$
Low
0.23
AU$
Shares On Issue
1.45B
52 Week Low
0.222
AU$
52 Week High
0.44
AU$
Website
www.immutep.com
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved